U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Gilead Sciences announced that the FDA has accepted its supplemental New Drug Application for once-weekly oral Yeztugo (lenacapavir) for HIV prevention. The FDA assigned a Prescription Drug User Fee Act action date of February 2, 2027, with the submission supported by data from the PURPOSE 1 and PURPOSE 2 trials.
Key figures
- Drug Name
- Yeztugo (lenacapavir)
- Dosage
- 300-mg tablet
- Frequency
- once-weekly
- Indication
- pre-exposure prophylaxis (PrEP)
- Pdufa date
- February 2, 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.